Tc-99m Pentetate
PreclinicalSmall molecule
Tc-99m Pentetate is one of 3 small molecule programs targeting Renal Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Renal Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Tc-99m Pentetate
NNYU Langone Health
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tc-99m Pentetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNYU Langone Health